These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 31879277)

  • 41. Impact of pneumococcal conjugate vaccines on burden of invasive pneumococcal disease and serotype distribution of Streptococcus pneumoniae isolates: an overview from Kuwait.
    Mokaddas E; Albert MJ
    Vaccine; 2012 Dec; 30 Suppl 6():G37-40. PubMed ID: 23228356
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Late onset of injection site reactions after vaccination with the 13-valent pneumococcal conjugate vaccine in adult study populations.
    Juergens C; Trammel J; Shoji Y; Patterson S; Watson W; Webber C; Gruber WC; Scott DA; Schmoele-Thoma B
    Hum Vaccin Immunother; 2018; 14(8):1948-1956. PubMed ID: 29543583
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Two pneumococcal vaccines: the 7-valent conjugate vaccine (Prevenar) for children up to the age of 5 years and the 23-valent polysaccharide vaccine (Pneumo 23) for the elderly and specific groups at risk].
    de Greeff SC; Sanders EA; de Melker HE; van der Ende A; Vermeer PE; Schouls LM
    Ned Tijdschr Geneeskd; 2007 Jun; 151(26):1454-7. PubMed ID: 17633974
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cost-effectiveness of pneumococcal conjugate vaccination in Croatia.
    Vučina VV; Filipović SK; Kožnjak N; Stamenić V; Clark AD; Mounaud B; Blau J; Hoestlandt C; Kaić B
    Vaccine; 2015 May; 33 Suppl 1():A209-18. PubMed ID: 25919163
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Impacts of the 13-Valent Pneumococcal Conjugate Vaccine in Children.
    Esposito S; Principi N
    J Immunol Res; 2015; 2015():591580. PubMed ID: 26351648
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Differences in attitudes, beliefs and knowledge of hospital health care workers and community doctors to vaccination of older people.
    Ridda I; Lindley IR; Gao Z; McIntyre P; Macintyre CR
    Vaccine; 2008 Oct; 26(44):5633-40. PubMed ID: 18706955
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pneumococcal vaccination programs and the burden of invasive pneumococcal disease in Ontario, Canada, 1995-2011.
    Rudnick W; Liu Z; Shigayeva A; Low DE; Green K; Plevneshi A; Devlin R; Downey J; Katz K; Kitai I; Krajden S; Ostrowska K; Richardson D; Richardson S; Sarabia A; Silverman M; Simor AE; Tyrrell G; McGeer A;
    Vaccine; 2013 Dec; 31(49):5863-71. PubMed ID: 24099873
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Provider adoption of pneumococcal conjugate vaccine and the impact of vaccine shortages.
    Daley MF; Crane LA; Beaty BL; Barrow J; Pearson K; Stevenson JM; Berman S; Kempe A
    Ambul Pediatr; 2005; 5(3):157-64. PubMed ID: 15913409
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pneumococcal vaccination of elderly adults: new paradigms for protection.
    Jackson LA; Janoff EN
    Clin Infect Dis; 2008 Nov; 47(10):1328-38. PubMed ID: 18844484
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Vaccine-preventable severe morbidity and mortality caused by meningococcus and pneumococcus: A population-based study in France.
    Lorton F; Chalumeau M; Assathiany R; Martinot A; Bucchia M; Roué JM; Bourgoin P; Chantreuil J; Boussicault G; Gaillot T; Saulnier JP; Caillon J; Levy C; Cohen R; Gras-Le Guen C; Launay E
    Paediatr Perinat Epidemiol; 2018 Sep; 32(5):442-447. PubMed ID: 30170336
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Adult vaccination for pneumococcal disease: a comparison of the national guidelines in Europe.
    Bonnave C; Mertens D; Peetermans W; Cobbaert K; Ghesquiere B; Deschodt M; Flamaing J
    Eur J Clin Microbiol Infect Dis; 2019 Apr; 38(4):785-791. PubMed ID: 30778705
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effectiveness of 7-valent pneumococcal conjugate vaccine in the prevention of invasive pneumococcal disease in children aged 7-59 months. A matched case-control study.
    Domínguez A; Ciruela P; García-García JJ; Moraga F; de Sevilla MF; Selva L; Coll F; Muñoz-Almagro C; Planes AM; Codina G; Jordán I; Esteva C; Hernández S; Soldevila N; Cardeñosa N; Batalla J; Salleras L
    Vaccine; 2011 Nov; 29(48):9020-5. PubMed ID: 21939724
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pneumococcal vaccination in adults: recommendations, trends, and prospects.
    Targonski PV; Poland GA
    Cleve Clin J Med; 2007 Jun; 74(6):401-6, 408-10, 413-4. PubMed ID: 17569198
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The future of pneumococcal disease prevention.
    Rodgers GL; Klugman KP
    Vaccine; 2011 Sep; 29 Suppl 3():C43-8. PubMed ID: 21896352
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Childhood invasive pneumococcal disease in Germany between 1997 and 2003: variability in incidence and serotype distribution in absence of general pneumococcal conjugate vaccination.
    Rückinger S; von Kries R; Reinert RR; van der Linden M; Siedler A
    Vaccine; 2008 Jul; 26(32):3984-6. PubMed ID: 18495301
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Pneumococcal vaccination in patients with systemic lupus erythematosus: A multicenter placebo-controlled randomized double-blind study.
    Grabar S; Groh M; Bahuaud M; Le Guern V; Costedoat-Chalumeau N; Mathian A; Hanslik T; Guillevin L; Batteux F; Launay O;
    Vaccine; 2017 Sep; 35(37):4877-4885. PubMed ID: 28784280
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Immunogenicity and impact on disease activity of influenza and pneumococcal vaccines in systemic lupus erythematosus: a systematic literature review and meta-analysis.
    Pugès M; Biscay P; Barnetche T; Truchetet MÉ; Richez C; Seneschal J; Gensous N; Lazaro E; Duffau P
    Rheumatology (Oxford); 2016 Sep; 55(9):1664-72. PubMed ID: 27160278
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Antibiotic resistance and the potential impact of pneumococcal conjugate vaccines.
    Dagan R
    Commun Dis Intell Q Rep; 2003; 27 Suppl():S134-42. PubMed ID: 12807290
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pneumococcal and Meningococcal Vaccination among Michigan Children with Sickle Cell Disease.
    Wagner AL; Shrivastwa N; Potter RC; Lyon-Callo SK; Boulton ML
    J Pediatr; 2018 May; 196():223-229. PubMed ID: 29555094
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A quality improvement project significantly increased the vaccination rate for immunosuppressed patients with IBD.
    Parker S; Chambers White L; Spangler C; Rosenblum J; Sweeney S; Homan E; Bensen SP; Levy LC; Dragnev MC; Moskalenko-Locke K; Rich P; Siegel CA
    Inflamm Bowel Dis; 2013 Aug; 19(9):1809-14. PubMed ID: 23714677
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.